Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 7/20 | 1.00 |
| ▸ | USP2 | O75604 | 6/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 5/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 5/20 | 1.00 |
| ▸ | TP53 | P04637 | 5/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 4/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 4/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
| ▸ | THPO | P40225 | 3/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 1.00 |
| ▸ | KCNK2 | O95069 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 8/20 | 0.98 |
| ▸ | MEN1 | O00255 | 7/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.98 |
| ▸ | RAD52 | P43351 | 3/20 | 0.98 |
| ▸ | GMNN | O75496 | 3/20 | 0.98 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.98 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.98 |
| ▸ | HTR1A | P08908 | 4/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Z-Flupentixol SCHEMBL34200 | 1.00 | CYP3A4 (1.00) | CYP3A4USP2SIGMAR1CYP2D6MAPK1 | |
| E-Flupentixol SCHEMBL30596168 | 1.00 | CYP3A4 (1.00) | CYP3A4USP2SIGMAR1CYP2D6MAPK1 | |
| E-Flupentixol SCHEMBL29598791 | 1.00 | CYP3A4 (1.00) | CYP3A4USP2SIGMAR1CYP2D6MAPK1 | |
| Z-Flupentixol SCHEMBL29361845 | 1.00 | CYP3A4 (1.00) | CYP3A4USP2SIGMAR1CYP2D6MAPK1 | |
| E-Flupentixol SCHEMBL414352 | 1.00 | CYP3A4 (1.00) | CYP3A4USP2SIGMAR1CYP2D6MAPK1 | |
| Z-Flupentixol SCHEMBL29620416 | 1.00 | CYP3A4 (1.00) | CYP3A4USP2SIGMAR1CYP2D6MAPK1 | |
| Z-Flupentixol SCHEMBL1153162 | 0.99 | LMNA (1.00) | CYP3A4USP2SIGMAR1CYP2D6MAPK1 | |
| E-Flupentixol SCHEMBL11427109 | 0.99 | LMNA (1.00) | CYP3A4USP2SIGMAR1CYP2D6MAPK1 | |
| E-Flupentixol SCHEMBL1230220 | 0.99 | LMNA (1.00) | CYP3A4USP2SIGMAR1CYP2D6MAPK1 | |
| Z-Flupentixol SCHEMBL719323 | 0.99 | LMNA (1.00) | CYP3A4USP2SIGMAR1CYP2D6MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 5289 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | claimed |
| US-12550885-B2 | Red blood cell storage solutions, solution additives, and methods for improving the storage of red blood cells | UNIVERSITY OF CINCINNATI (US) | 2026-02-17 | — | — | US | claimed |
| US-12527754-B2 | Methods and compositions for preventing and treating metabolic syndrome induced by antipsychotic treatment and related diseases and conditions | TUFTS MEDICAL CENTER, INC. (US) | 2026-01-20 | — | — | US | claimed |
| EP-4654963-A1 | TREATMENT OF MENTAL ILLNESS VIA ADMINISTRATION OF BUNTANETAP AND ANALOGUES THEREOF | Annovis Bio, Inc. (US) | 2025-12-03 | — | — | EP | claimed |
| US-20250295674-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF CNS-RELATED DISORDERS | SAGE THERAPEUTICS, INC. | 2025-09-25 | — | — | US | claimed |
| EP-4618973-A1 | METHODS OF SWITCHING NEUROPSYCHIATRIC MEDICATIONS USING ULOTARONT | Sumitomo Pharma America, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| US-20250238922-A1 | MACHINE-LEARNING SYSTEM FOR DIAGNOSING DISORDERS AND DISEASES AND DETERMINING DRUG RESPONSIVENESS | Sanford Burnham Prebys Medical Discovery Institute | 2025-07-24 | — | — | US | claimed |
| US-20250213647-A1 | CHEMOKINE RECEPTORS AND ALPHA1 ADRENERGIC RECEPTORS/VASOPRESSIN RECEPTORS 1A HETEROMERS AS DRUG TARGETS FOR DISEASE | UNIVERSITY OF SOUTH FLORIDA | 2025-07-03 | — | — | US | claimed |
| US-20250177418-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF GASTROINTESTINAL DISEASES OR CONDITIONS | SAGE THERAPEUTICS, INC. | 2025-06-05 | — | — | US | claimed |
| US-20250179064-A1 | BENZOQUINOLONE INHIBITORS OF VMAT2 | AUSPEX PHARMACEUTICALS LLC | 2025-06-05 | — | — | US | claimed |
| CN-1215322-A | Method for encapsulating caplets in capsules and solid dosage forms obtainable by this method | WARNER LAMBERT CO (US) | 1999-04-28 | — | — | CN | claimed |
| EP-0891180-A1 | PROCESS FOR ENCAPSULATION OF CAPLETS IN A CAPSULE AND SOLID DOSAGE FORMS OBTAINABLE BY SUCH PROCESS | WARNER-LAMBERT COMPANY (US) | 1999-01-20 | — | — | EP | claimed |
| WO-1998018610-A1 | EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE PARTICLES | LENGERICH BERNHARD H VAN (US) | 1998-05-07 | — | — | WO | claimed |
| CN-1170346-A | Process for encapsulation of caplets in capsule and solid dasage forms obtainable by such process | WARNER LAMBERT CO (US) | 1998-01-14 | — | — | CN | claimed |
| WO-1998000159-A1 | USEFUL FORMULATIONS OF ACID ADDITION SALT DRUGS | OXIGENE, INC. (US) | 1998-01-08 | — | — | WO | claimed |
| WO-1997037629-A1 | PROCESS FOR ENCAPSULATION OF CAPLETS IN A CAPSULE AND SOLID DOSAGE FORMS OBTAINABLE BY SUCH PROCESS | WARNER-LAMBERT COMPANY (US) | 1997-10-16 | — | — | WO | claimed |
| EP-0797424-A1 | PROCESS FOR ENCAPSULATION OF CAPLETS IN A CAPSULE AND SOLID DOSAGE FORMS OBTAINABLE BY SUCH PROCESS | WARNER-LAMBERT COMPANY (US) | 1997-10-01 | — | — | EP | claimed |
| WO-1996018370-A1 | PROCESS FOR ENCAPSULATION OF CAPLETS IN A CAPSULE AND SOLID DOSAGE FORMS OBTAINABLE BY SUCH PROCESS | WARNER-LAMBERT COMPANY (US) | 1996-06-20 | — | — | WO | claimed |
| EP-0428754-B1 | HAIR GROWTH STIMULANT | SHISEIDO CO LTD (JP) | 1994-05-25 | — | — | EP | claimed |
| EP-0428754-A1 | HAIR GROWTH STIMULANT | SHISEIDO COMPANY LIMITED (JP) | 1991-05-29 | — | — | EP | claimed |